MOLN
$4.34
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinic...
Recent News
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready
Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its DLL3-targeting radiotherapeutic program, following a presentation at the Theranostics World Conference in South Africa. Company executives said the data came from a named patient access p
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company
Key Insights Given the large stake in the stock by institutions, Molecular Partners' stock price might be vulnerable to...
Stocks Look Set to Open Trading Session Marginally Lower Wednesday as Investors Look Ahead to Nvidia Earnings
US stocks look set to open flat in Wednesday's trading session as investors await Nvidia's Q2 result
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.